Roche—Tecentriq/Avastin shows statisg-better PFS vs Sutent monotherapy in first-line RCC for PD-L1-positive subgroup, but not for entire phase-2 trial:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.